Biodegradable Ocular Insert for Sustained Glucocorticoid Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic conjunctivitis, such as topical ophthalmic formulations, require multiple daily dosages, leading to inconvenience and reduced treatment compliance. Additionally, existing formulations, especially eye drops, can result in inconsistent dosing and potential drug abuse.
Innovation Solution
A biodegradable ocular insert is administered into the superior and/or inferior canaliculus of the eye, providing a sustained release of a glucocorticoid like dexamethasone, thereby reducing the frequency of dosing and improving treatment compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical ophthalmic formulations are used, then allergic conjunctivitis can be treated, but multiple daily dosages are required leading to reduced treatment compliance
Solution Approach 1:
The ocular insert provides continuous release of glucocorticoid medication over an extended period (typically 30 days), eliminating the need for multiple daily dosing. The sustained release mechanism maintains therapeutic drug levels continuously in the ocular environment, ensuring consistent treatment effect without requiring patient compliance with frequent dosing schedules.
Solution Approach 2:
The insert is self-regulating in that it automatically releases medication at a controlled rate without requiring patient intervention. Once inserted into the canaliculus, the device autonomously maintains therapeutic levels through its sustained release mechanism, freeing the patient from the burden of repeated dosing actions.
2Ease of manufacture
If eye drops are used, then treatment is readily available, but inconsistent dosing and potential drug abuse occur
Solution Approach 1:
The invention changes the physical state and release parameters of the medication from immediate-release liquid drops to a controlled-sustained-release solid insert. This parameter change transforms the dosing profile from variable and user-dependent to consistent and device-controlled, ensuring precise and reproducible drug delivery over time.
Solution Approach 2:
The ocular insert acts as an intermediary device between the medication and the ocular environment. It controls the interface and release kinetics, ensuring consistent dosing by mediating the transfer of glucocorticoid from the insert matrix to the tear fluid, thereby eliminating the dosing inconsistencies associated with direct eye drop administration.
3Reliability
If frequent dosing is required, then symptom relief can be maintained, but treatment convenience decreases
Solution Approach 1:
The sustained release insert maintains continuous therapeutic action for approximately 30 days, providing uninterrupted symptom relief without requiring the patient to perform repeated dosing actions. This continuous delivery mechanism ensures consistent glucocorticoid levels are maintained in the ocular environment, reliably controlling allergic conjunctivitis symptoms.
Solution Approach 2:
The medication is pre-loaded into the insert in a sustained-release formulation before insertion. This preliminary preparation ensures that the full course of treatment is contained within the device, which then automatically administers the medication over time without requiring further patient action, thereby maintaining symptom relief convenience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release of dexamethasone from the ocular insert effectively reduces ocular itching and conjunctival redness associated with allergic conjunctivitis, providing longer-lasting relief compared to traditional treatments.
Implementation Method 1
the insert provides sustained release of a glucocorticoid
Implementation Method 2
sustained release biodegradable intracanalicular insert comprising a hydrogel
Data Source
AI summary
Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis.